# EDGAR Filing Document

**Accession Number:** 0001138978
**File Stem:** 0001493152-23-008805
**Filing Date:** 2023-3
**Character Count:** 13615
**Document Hash:** d39fa423b2e4b50e3d45f6b61e5750cd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-008805.hdr.sgml**: 20230324

**ACCESSION NUMBER**: 0001493152-23-008805

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230324

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230324

**DATE AS OF CHANGE**: 20230324

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Novo Integrated Sciences, Inc.
- **CENTRAL INDEX KEY:** 0001138978
- **STANDARD INDUSTRIAL CLASSIFICATION:** ENGINES & TURBINES [3510]
- **IRS NUMBER:** 593691650
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0831

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40089
- **FILM NUMBER:** 23757852

**BUSINESS ADDRESS:**
- **STREET 1:** 11120 NE 2ND STREET
- **STREET 2:** SUITE 100
- **CITY:** BELLEVUE
- **STATE:** WA
- **ZIP:** 98004
- **BUSINESS PHONE:** (206) 617-9797

**MAIL ADDRESS:**
- **STREET 1:** 11120 NE 2ND STREET
- **STREET 2:** SUITE 100
- **CITY:** BELLEVUE
- **STATE:** WA
- **ZIP:** 98004

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TURBINE TRUCK ENGINES INC
- **DATE OF NAME CHANGE:** 20010420

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest reported): **March 24, 2023**

**Novo Integrated Sciences, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Nevada** | **001-40089** | **59-3691650** |
| (State or other jurisdiction | (Commission | (IRS Employer |
| of Incorporation) | File Number) | Identification Number) |

---

**<u>11120 NE 2nd Street, Suite 200, Bellevue, WA 98004</u>**

(Address of principal executive offices)

**<u>(206) 617-9797</u>**

(Registrant's telephone number, including area code)

**<u>N/A</u>**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.)

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CF$240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on which Registered |
| Common Stock | NVOS | Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01. Other Events.**

As previously disclosed in the Current Report on Form 8-K filed with the Securities and Exchange Commission on December 21, 2022 by Novo Integrated Sciences, Inc. (the "Company"), on December 15, 2022, the Company received a notice on December 15, 2022 (the "December Nasdaq Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") advising the Company that it was not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the "Rule") as a result of its failure to timely file its Annual Report on Form 10-K for the fiscal year ended August 31, 2022 (the "Form 10-K"). On January 26, 2023, the Company reported that it received a notice (the "January Nasdaq Notice") on January 25, 2023 from Nasdaq advising the Company that it was not in compliance with Nasdaq's continued listing requirements under the Rule as a result of its failure to timely file the Form 10-K and its Quarterly Report on Form 10-Q for the fiscal quarter ended November 30, 2022 (the "Form 10-Q").

Per the January Nasdaq Notice and in accordance with the December Nasdaq Notice, the Company had 60 calendar days from receipt of the December Nasdaq Notice or until February 13, 2023, to submit a plan to regain compliance with the Rule with the respect to the Form 10-K and the Form 10-Q. On February 13, 2023, the Company submitted to Nasdaq its plan to regain compliance with the Rule with respect to the Form 10-K and the Form 10-Q. If Nasdaq accepted the Company's plan, then Nasdaq could grant an exception of up to 180 calendar days from the due date of the Form 10-K to regain compliance.

On February 17, 2023 and March 22, 2023, based on Nasdaq's further review, Nasdaq granted an exception to enable the Company to regain compliance with the Rule. The terms of the exception are as follows: on or before May 29, 2023, the Company must file its Form 10-K for the period ended August 31, 2022; its Form 10-Q for the period ended November 30, 2022, and any other filings required by the Rule.

On March 24, 2023, the Company issued a press release providing an update regarding certain actions and events, including with respect to the grant of an exception by Nasdaq as described above. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press release issued by the registrant on March 24, 2023.](ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Novo Integrated Sciences, Inc.** | **Novo Integrated Sciences, Inc.** |
| Dated: March 24, 2023 | By: | */s/ Robert Mattacchione* |
|  |  | Robert Mattacchione |
|  |  | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**Novo Integrated Sciences Provides Update on Certain Current Actions and Events**

**BELLEVUE, Wash., March 24, 2023 -** Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the "Company" or "Novo"), today provides an update with respect to certain actions and events, as follows:

● As previously reported, on December 23, 2022, Novo entered into a Share Purchase Agreement (the "SWAG Agreement") with SwagCheck Inc. ("SWAG") and the shareholders of SWAG, pursuant to which Novo agreed to purchase 100% of SWAG's outstanding shares. SWAG holds a specific right of purchase of a precious gem collection as provided for in an agreement between SWAG and a Court-appointed Successor Receiver for the United States District Court for the Central District of California. Pursuant to the terms of the SWAG Agreement, as amended, the SWAG Agreement was to close no later than January 10, 2023. Although the SWAG Agreement has not yet closed, the parties continue to work together with the intention of closing the transaction.

● As previously reported, on December 15, 2022 and January 25, 2023, the Company was notified that it did not comply with Nasdaq's filing requirements set forth in Listing Rule 5250(c)(1) (the "Rule") because it had not filed its Form 10-K for the year ended August 31, 2022 and its Form 10-Q for the period ended November 30, 2022 (the "Delinquent Filings") respectively. On February 17, 2023 and March 22, 2023, based on Nasdaq's further review, Nasdaq granted an exception to enable the Company to regain compliance with the Rule. The terms of the exception are as follows: on or before May 29, 2023, the Company must file its Form 10-K for the period ended August 31, 2022; its Form 10-Q for the period ended November 30, 2022, and any other filings required by the Rule.

● Between February 13, 2023 and March 23, 2023 the Company issued 4,100,687 shares of common stock to certain note holders upon conversion of their notes.

● As previously reported, on February 24, 2023, under the terms and conditions of a securities purchase agreement, dated February 23, 2023, the Company issued 955,000 restricted shares of common stock.

● On March 17, 2023 , under the terms and conditions of a 3-year Warrant Agreement, dated October 18, 2022, 1,600,000 shares were issued for proceeds of $160,000.

● On March 17, 2023, under the terms and conditions of a 5-year Warrant Agreement, dated October 18, 2022, 1,000,000 shares were issued for proceeds of $100,000.

● On March 22, 2023, under the terms and conditions of a securities purchase agreement, dated March 21, 2023, the Company issued 955,000 restricted shares of common stock.

● As of March 23, 2023, the Company's issued and outstanding common share count is 144,257,518.

● As of March 23, 2023, the principal balance owed by the Company pursuant to the senior secured convertible note, dated as of December 14, 2021, as amended, issued by the Company to CVI Investments, Inc. is $0.00, the principal balance owed by the Company pursuant to the senior secured convertible note, dated as of December 14, 2021, as amended, issued by the Company to Hudson Bay Master Fund Ltd is $50,000, and the principal balance owed by the Company pursuant to the secured convertible promissory note, dated as of November 17, 2021, issued by the Company to Jefferson Street Capital LLC is $0.00.

**<u>About Novo Integrated Sciences, Inc.</u>**

Novo Integrated Sciences, Inc. is pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation. Novo offers an essential and differentiated solution to deliver, or intend to deliver, these services and products through the integration of medical technology, diagnostic and therapeutic solutions, and rehabilitative science.

We believe that "decentralizing" healthcare, through the integration of medical technology and interconnectivity, is an essential solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered both now and in the future. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient's home and away from on-site visits to primary medical centers with mass-services. This acceleration of "ease-of-access" in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective healthcare distribution.

Innovation through science combined with the integration of sophisticated, secure technology assures Novo Integrated Sciences of continued cutting-edge advancement in patient-first platforms.

For more information concerning Novo Integrated Sciences, please visit **<u>www.novointegrated.com</u>**. For more information on Novo Healthnet Limited, Novo's wholly owned subsidiary, please visit **<u>www.novohealthnet.com.</u>**

<u>Twitter</u>, <u>LinkedIn</u>, <u>Facebook</u>, <u>Instagram</u>, <u>YouTube</u>

**<u>Forward-Looking Statements</u>**

This press release contains forward-looking statements. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as "believe," "intend," "expect," "anticipate," "plan," "potential," "continue," or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks, and uncertainties are discussed in Novo's filings with the Securities and Exchange Commission. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown uncertainties and other factors which are, in some cases, beyond Novo's control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Novo's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Novo assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The contents of any website referenced in this press release are not incorporated by reference herein.

Chris David, COO & President<br> Novo Integrated Sciences, Inc.<br> **<u>chris.david@novointegrated.com</u>**<br> (888) 512-1195